You may also like
Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19
For now—and possibly the next 18 to 24 months, convalescent plasma, despite supply issues and questions about efficacy and who is most likely to benefit from treatment, remains the only off-the-shelf therapy for COVID-19.
1 min read
Mitral Transcatheter Technologies
Mitral valve regurgitation (MR) is often diagnosed in patients with heart failure and is associated with worsening of symptoms and reduced survival.
1 min read
MC3 Cardiopulmonary Acquires Surgical Cannula Product Assets from Terumo Cardiovascular Systems
MC3 Cardiopulmonary today announced it has completed the acquisition and transfer of all assets associated with Terumo Cardiovascular's previously marketed Surgical Cannula line, including leading brand names like Sarns™ Soft-Flow® Arterial Cannula.
1 min read